SeekingAlphaOctober 10, 2026 at 5:08 AM NY17 Days Ago
Krystal Biotech: Vyjuvek's Success Is Becoming Its Growth Problem (Downgrade)
Krystal Biotech is downgraded from Buy to Hold as U.S. VYJUVEK sales plateau and growth shifts ex-U.S. Read more on KRYS stock here.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: SeekingAlpha
